Yi-Wei Wang1, Xiaotu Ma2, Yu-An Zhang3, Mei-Jung Wang4, Yasushi Yatabe5, Stephen Lam6, Luc Girard3, Jeou-Yuan Chen7, Adi F Gazdar8. 1. Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas; Institute of Biomedical Sciences, Academia Sinica, Taipei, Republic of China. 2. The Center for Systems Biology, Department of Molecular and Cell Biology, The University of Texas at Dallas, Richardson, Texas. 3. Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas. 4. Institute of Biomedical Sciences, Academia Sinica, Taipei, Republic of China. 5. Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan. 6. British Columbia Cancer Research Center, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. 7. Institute of Biomedical Sciences, Academia Sinica, Taipei, Republic of China; Department of Life Sciences and Institute of Genome Sciences, National Yang-Ming University, Taipei, Republic of China. 8. Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas; Department of Pathology and Harold Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: adi.gazdar@utsouthwestern.edu.
Abstract
INTRODUCTION: Despite recent advances in cancer therapy, the overall 5-year survival rate of patients with lung cancer remains low. The aim of our study was to search for novel markers for early diagnosis in patients with lung cancer. METHODS: Complementary DNA microarray analysis was performed in primary lung adenocarcinomas and cell lines to search for differentially expressed genes, followed by in vivo and in vitro tumorigenic assays to characterize the oncogenic potential of the candidate genes. Gene body methylation was analyzed by 450K methylation array, bisulfite sequencing, and quantitative methylation-specific polymerase chain reaction assays. In silico analysis of The Cancer Genome Atlas data set was also performed. RESULTS: Inositol-trisphosphate 3-kinase A gene (ITPKA), a kinase with limited tissue distribution, was identified as a potential oncogene. We showed that ITPKA expression is up-regulated in many forms of cancers, including lung and breast cancers, and that overexpressed ITPKA contributes to tumorigenesis. We also demonstrated that ITPKA expression is regulated by epigenetic DNA methylation of ITPKA gene body through modulation of the binding of SP1 transcription factor to the ITPKA promoter. ITPKA gene body displayed low or absent levels of methylation in most normal tissue but was significantly methylated in malignant tumors. In lung cancer, ITPKA gene body methylation first appeared at the in situ carcinoma stage and progressively increased after invasion. CONCLUSIONS: ITPKA is a potential oncogene that it is overexpressed in most tumors, and its overexpression promotes tumorigenesis. ITPKA gene body methylation regulates its expression and thus serves as a novel and potential biomarker for early cancer detection.
INTRODUCTION: Despite recent advances in cancer therapy, the overall 5-year survival rate of patients with lung cancer remains low. The aim of our study was to search for novel markers for early diagnosis in patients with lung cancer. METHODS: Complementary DNA microarray analysis was performed in primary lung adenocarcinomas and cell lines to search for differentially expressed genes, followed by in vivo and in vitro tumorigenic assays to characterize the oncogenic potential of the candidate genes. Gene body methylation was analyzed by 450K methylation array, bisulfite sequencing, and quantitative methylation-specific polymerase chain reaction assays. In silico analysis of The Cancer Genome Atlas data set was also performed. RESULTS:Inositol-trisphosphate 3-kinase A gene (ITPKA), a kinase with limited tissue distribution, was identified as a potential oncogene. We showed that ITPKA expression is up-regulated in many forms of cancers, including lung and breast cancers, and that overexpressed ITPKA contributes to tumorigenesis. We also demonstrated that ITPKA expression is regulated by epigenetic DNA methylation of ITPKA gene body through modulation of the binding of SP1 transcription factor to the ITPKA promoter. ITPKA gene body displayed low or absent levels of methylation in most normal tissue but was significantly methylated in malignant tumors. In lung cancer, ITPKA gene body methylation first appeared at the in situ carcinoma stage and progressively increased after invasion. CONCLUSIONS:ITPKA is a potential oncogene that it is overexpressed in most tumors, and its overexpression promotes tumorigenesis. ITPKA gene body methylation regulates its expression and thus serves as a novel and potential biomarker for early cancer detection.
Authors: M Sanchez-Cespedes; M Esteller; L Wu; H Nawroz-Danish; G H Yoo; W M Koch; J Jen; J G Herman; D Sidransky Journal: Cancer Res Date: 2000-02-15 Impact factor: 12.701
Authors: Diane I Schroeder; John D Blair; Paul Lott; Hung On Ken Yu; Danna Hong; Florence Crary; Paul Ashwood; Cheryl Walker; Ian Korf; Wendy P Robinson; Janine M LaSalle Journal: Proc Natl Acad Sci U S A Date: 2013-03-25 Impact factor: 11.205
Authors: J G Herman; A Merlo; L Mao; R G Lapidus; J P Issa; N E Davidson; D Sidransky; S B Baylin Journal: Cancer Res Date: 1995-10-15 Impact factor: 12.701
Authors: Sipeng Shen; Ruyang Zhang; Yichen Guo; Elizabeth Loehrer; Yongyue Wei; Ying Zhu; Qianyu Yuan; Sebastian Moran; Thomas Fleischer; Maria M Bjaanaes; Anna Karlsson; Maria Planck; Johan Staaf; Åslaug Helland; Manel Esteller; Li Su; Feng Chen; David C Christiani Journal: Mol Oncol Date: 2018-05-04 Impact factor: 6.603
Authors: Helen R Moinova; Thomas LaFramboise; James D Lutterbaugh; Apoorva Krishna Chandar; John Dumot; Ashley Faulx; Wendy Brock; Omar De la Cruz Cabrera; Kishore Guda; Jill S Barnholtz-Sloan; Prasad G Iyer; Marcia I Canto; Jean S Wang; Nicholas J Shaheen; Prashanti N Thota; Joseph E Willis; Amitabh Chak; Sanford D Markowitz Journal: Sci Transl Med Date: 2018-01-17 Impact factor: 19.319
Authors: Michael H McGuire; Shelley M Herbrich; Santosh K Dasari; Sherry Y Wu; Ying Wang; Rajesha Rupaimoole; Gabriel Lopez-Berestein; Keith A Baggerly; Anil K Sood Journal: EBioMedicine Date: 2019-05-02 Impact factor: 8.143